Danish pharmaceutical company ALK-Abelló A/S (ALK) (CPH:ALK-B) announced on Thursday that the UK's National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX for the treatment of persistent, moderate to severe house dust mite allergic rhinitis in adults and adolescents.
This recommendation allows access to ACARIZAX via the National Health Service (NHS) in England, Wales, and Northern Ireland.
House dust mite allergy affects approximately half of the 26% of UK adults with allergic rhinitis.
ACARIZAX is the first sublingual allergy immunotherapy (AIT) recommended by NICE and available through the NHS. NICE's Final Guidance is expected in March, after which NHS implementation will follow.
ALK is preparing to submit a similar application for a NICE review of its sublingual tree tablet, ITULAZAX. Submissions will also be made to extend the approvals for ACARIZAX and ITULAZAX to include children.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval